Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 3940 (2021)

Differences in insulin dosing in women with type 1 diabetes before and after the menopause

  • Andreas Melmer
  • Irina Zürrer
  • Florian Kopp
  • Martin Pfeifer
  • Erna Kamml
  • Gabriele Götz
  • Sabine Hofer
  • Ingrid Schütz-Fuhrmann
  • Andreas Hungele
  • Reinhard W. Holl
DOI
https://doi.org/10.4414/SMW.2021.w30025
Cite this as:
Swiss Med Wkly. 2021;151:w30025
Published
30.09.2021

Summary

The menstrual cycle increases insulin requirements in a subset of women with type 1 diabetes as a result of reduced insulin action through sexual hormones. If exposure to sexual hormones declines during the menopause, adaptions of insulin dosing may be required. However, there are no validated recommendations available on how to adapt insulin treatment in postmenopausal women with type 1 diabetes. The present study compared insulin dosing profiles of 630 premenopausal and 548 postmenopausal women, who had long-term type 1 diabetes and used continuous subcutaneous insulin infusion. Data were extracted from the German "Diabetes-Patienten- Verlaufsdokumentation". 

It was found that total daily insulin (p <0.0001), daily insulin per kilogram bodyweight (p <0.0001), total daily basal insulin (p <0.0001), daily basal insulin per kilogram bodyweight (p <0.0001) and estimated glomerular filtration rate (eGFR) (p <0.0001) were lower in postmenopausal women. Total daily bolus insulin, daily bolus insulin per kilogram, glycated haemoglobin A1, body mass index and the incidence of severe hypoglycaemic events were similar in both cohorts.

Postmenopausal women with type 1 diabetes used lower insulin doses as compared with premenopausal women, whereas glycaemic control and body mass index were comparable. This observation might be explained by lower exposure to sexual hormones and lower eGFR, even though the contribution of other factors such as body composition and eating habits requires further investigation.

References

  1. Brown SA, Jiang B, McElwee-Malloy M, Wakeman C, Breton MD. Fluctuations of Hyperglycemia and Insulin Sensitivity Are Linked to Menstrual Cycle Phases in Women With T1D. J Diabetes Sci Technol. 2015 Oct;9(6):1192–9. https://doi.org/10.1177/1932296815608400
  2. Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 Feb;21(2):66–72. https://doi.org/10.1089/dia.2018.0384
  3. Group UK ; UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007 Jun;50(6):1140–7. https://doi.org/10.1007/s00125-007-0599-y
  4. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012 Nov;13(11):1141–51. https://doi.org/10.1016/S1470-2045(12)70425-4
  5. Barata DS, Adan LF, Netto EM, Ramalho AC. The effect of the menstrual cycle on glucose control in women with type 1 diabetes evaluated using a continuous glucose monitoring system. Diabetes Care. 2013 May;36(5):e70. https://doi.org/10.2337/dc12-2248
  6. Yeung EH, Zhang C, Mumford SL, Ye A, Trevisan M, Chen L, et al. Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: the BioCycle Study. J Clin Endocrinol Metab. 2010 Dec;95(12):5435–42. https://doi.org/10.1210/jc.2010-0702
  7. Berenson AB, van den Berg P, Williams KJ, Rahman M. Effect of injectable and oral contraceptives on glucose and insulin levels. Obstet Gynecol. 2011 Jan;117(1):41–7. https://doi.org/10.1097/AOG.0b013e318202ac23
  8. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women—a clinical research center study. J Clin Endocrinol Metab. 1996 Jun;81(6):2250–6.
  9. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia. 1984 Sep;27(3):351–7. https://doi.org/10.1007/BF00304849
  10. Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron J. 1975;15(3-5):306–26. https://doi.org/10.1159/000180518
  11. Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001 May;24(5):886–90. https://doi.org/10.2337/diacare.24.5.886
  12. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med. 2003 Aug;20(8):642–5. https://doi.org/10.1046/j.1464-5491.2003.01025.x
  13. Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013 Aug;4(4):113–21. https://doi.org/10.1177/2042018813501188
  14. Charpentier G, Riveline JP, and Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes & metabolism. 2000;26 Suppl 4(73-85.
  15. Gorczyca AM, Sjaarda LA, Mitchell EM, Perkins NJ, Schliep KC, Wactawski-Wende J, et al. Changes in macronutrient, micronutrient, and food group intakes throughout the menstrual cycle in healthy, premenopausal women. Eur J Nutr. 2016 Apr;55(3):1181–8. https://doi.org/10.1007/s00394-015-0931-0
  16. Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019 Mar;4(5):124865. https://doi.org/10.1172/jci.insight.124865
  17. LaBarbera AR, Miller MM, Ober C, Rebar RW. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol. 1988 Mar;16(3):115–22. https://doi.org/10.1111/j.1600-0897.1988.tb00180.x
  18. Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am. 1998 Dec;27(4):989–1006. https://doi.org/10.1016/S0889-8529(05)70051-7
  19. Yki-Järvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. N Engl J Med. 1986 Jul;315(4):224–30. https://doi.org/10.1056/NEJM198607243150404
  20. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes. 1982 Sep;31(9):795–801. https://doi.org/10.2337/diab.31.9.795
  21. Moncayo R, Moncayo HE. Autoimmunity and the ovary. Immunol Today. 1992 Jul;13(7):255–8. https://doi.org/10.1016/0167-5699(92)90006-S
  22. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, et al.; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003 Jan;138(1):1–9. https://doi.org/10.7326/0003-4819-138-1-200301070-00005

Most read articles by the same author(s)